The science behind Wegovy: how semaglutide acts on appetite and weight

Step 1: the hormone your gut already sends — and what semaglutide adds

After a meal, your gut releases a hormone called glucagon-like peptide-1, better known as GLP-1. It travels to receptors in the hypothalamus and brainstem, telling those areas the meal is done and appetite can ease. The problem for many people is that natural GLP-1 breaks down within minutes, so the signal fades fast. Semaglutide is a modified version of that same hormone, engineered with a fatty-acid chain that anchors it to albumin in the blood. That attachment extends its half-life to roughly a week, which is exactly why a once-weekly injection is enough to keep the signal active.

When semaglutide binds to GLP-1 receptors, it does two things simultaneously. In the gut, it slows gastric emptying, the rate at which food moves from the stomach into the small intestine. In the brain's appetite-regulating centres, it reduces the subjective drive to eat. Neither effect requires conscious effort; both happen at the level of physiology. The NHS medicine information page for semaglutide explains this dual action in plain terms. You can read about semaglutide more broadly, including how it compares across formulations, on our semaglutide overview, and if you are specifically researching research-grade options, our Peptide Sciences semaglutide page covers what that supplier offers.

Step 2: what happens at each dose as titration progresses

Treatment does not start at the full 2.4 mg maintenance dose. The prescriber follows a titration schedule that begins at 0.25 mg and moves upward through 0.5 mg, 1.0 mg and 1.7 mg before reaching 2.4 mg, with roughly four weeks at each level. This staged approach exists for a straightforward reason: the same mechanism that reduces appetite also slows digestion, and introducing the full effect immediately would cause significant nausea for most people. A question our prescribers hear most weeks is whether a slower titration means the medicine is not working yet, the answer is that the starter doses are doing exactly what they are designed to do, letting the gut adapt before the dose climbs further.

For some patients, the MHRA has now approved a higher 7.2 mg maintenance dose, including a dedicated single-dose pen approved on 14 April 2026. The titration to 7.2 mg follows the same graduated principle. Our Wegovy guide covers what the full dosing pathway looks like in practice, and if you want to understand the UK licensing context in detail, the Wegovy UK licence page sets that out clearly.

Step 3: the trial evidence, what the science actually showed

The central piece of evidence for Wegovy's weight-management effect is the STEP 1 trial, a 68-week study published in the New England Journal of Medicine. Adults with obesity or overweight plus a weight-related condition received 2.4 mg semaglutide weekly alongside lifestyle support. The average weight reduction was around 15%, compared with roughly 2.4% in the placebo group. That gap is large by the standards of any medicine. The result has since informed NICE's recommendation for semaglutide (Wegovy) and shaped how NHS weight management services use it.

Semaglutide's mechanism also has downstream effects on blood glucose and insulin sensitivity, which is one reason a related formulation, Ozempic, is licensed separately for type 2 diabetes, though Ozempic is not a weight-management medicine and the two should not be conflated. People who have read about their own experience on treatment will find real accounts collected on our Wegovy experiences page. On the cost side of the decision, an honest breakdown of what private treatment involves is on our weight-loss treatments page.

Step 4: what the science means for nutrition and longer-term health

Reduced appetite sounds straightforwardly positive, but the biology creates a practical challenge worth understanding. When people eat significantly less, getting enough protein, iron, B12 and other micronutrients from a smaller food volume becomes harder. The slower gastric transit can also affect how supplements are absorbed. This is not a theoretical concern, it is why prescribers typically discuss dietary quality alongside treatment, and why some patients find it worth reviewing their intake of key vitamins. Our Wegovy and vitamin deficiency page looks at this in more depth.

The broader picture from the science is that Wegovy addresses weight through genuine biological pathways, not stimulant effects or diuresis. Weight lost on treatment reflects fat mass reduction, and the appetite changes persist for as long as the medicine is active. That is also why stopping treatment without a plan in place is something to discuss with a prescriber, the biology does not permanently change, so a structured approach to transition matters. If any of this prompts questions specific to your own health, the right next step is a clinical conversation rather than a forum. You can begin that with our prescribers at any time by starting your free consultation on the weight-loss treatments page.